Journey Medical Corporation Annual report pursuant to Section 13 and 15(d)

INTANGIBLES (Details)

INTANGIBLES (Details) - USD ($)		1 Months Ended	12 Months Ended
INTANGIBLES (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2022
Amzeeq intangible
Intangibles
Identifiable Intangibles				$ 15,200,000
Zilxi intangible
Intangibles
Identifiable Intangibles				3,800,000
Vyne product acquisition \| Amzeeq intangible
Intangibles
Identifiable Intangibles				15,162,000
Vyne product acquisition \| Zilxi intangible
Intangibles
Identifiable Intangibles				$ 3,760,000
Anti-itch product
Intangibles
Useful life			3 years
Accutane
Intangibles
Useful life			5 years
Asset purchase agreement \| Qbrexza
Intangibles
Upfront fees		$ 12,500,000
Milestone payments payable	$ 144,000,000	$ 144,000,000
Percentage of diminution in royalty	50.00%
Age of patients	9 years
Stay period	30 months
Purchase price	$ 12,500,000
Useful life	7 years
Asset purchase agreement \| Qbrexza \| Royalty payment percentage for first two years
Intangibles
Period of royalty payments	2 years
Asset purchase agreement \| Qbrexza \| Royalty payment percentage for eight years thereafter
Intangibles
Term of royalty	8 years
Asset purchase agreement \| Qbrexza \| Minimum \| Royalty payment percentage for first two years
Intangibles
Percent of royalty payments	30.00%
Asset purchase agreement \| Qbrexza \| Minimum \| Royalty payment percentage for eight years thereafter
Intangibles
Percent of royalty payments	12.00%
Asset purchase agreement \| Qbrexza \| Maximum \| Royalty payment percentage for first two years
Intangibles
Percent of royalty payments	40.00%
Asset purchase agreement \| Qbrexza \| Maximum \| Royalty payment percentage for eight years thereafter
Intangibles
Percent of royalty payments	19.00%